Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Blanchette

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Journal of Medical Economics|November 6, 2014
Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the USChristopher M Blanchette, Christopher Craver, Kathy W Belk, et al.
Current Medical Research and Opinion|September 7, 2010
Adherence to controller therapy for chronic obstructive pulmonary disease: a reviewMeaghan St Charles, Christopher M Blanchette, Harris Silver, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 12, 2011
Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary diseaseAnand A Dalal, Melissa H Roberts, Hans V Petersen, et al.
Drugs in Context|August 16, 2014
One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USASusan Tsivitse Arthur, Joshua M Noone, Bryce A Van Doren, et al.
Archives of Internal Medicine|January 26, 2005
Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid populationFadia T Shaya, Steven W Blume, Christopher M Blanchette, et al.
Drugs in Context|March 14, 2015
Cachexia & debility diagnoses in hospitalized children and adolescents with complex chronic conditions: evidence from the Kids' Inpatient DatabaseBryce A Van Doren, Debosree Roy, Joshua M Noone, et al.
Advances in Therapy|April 29, 2006
Resource utilization and costs of blood management services associated with knee and hip surgeries in US hospitalsChristopher M Blanchette, Peter Feng Wang, Ashish V Joshi, et al.
Clinicoeconomics and Outcomes Research : CEOR|January 23, 2015
End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseasesSteven M Brunelli, Christopher M Blanchette, Ami J Claxton, et al.
BMC Pulmonary Medicine|November 16, 2024
Higher healthcare cost and utilization before and after diagnosis of AATD in the United StatesChristopher M Blanchette, Sarah Whitmire, Joshua Oh, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 10, 2010
Quarterly assessment of short-acting beta(2)-adrenergic agonist use as a predictor of subsequent health care use for asthmatic patients in the United StatesHarris S Silver, Christopher M Blanchette, Shital Kamble, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Journal of Medical Economics|November 6, 2014
Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the USChristopher M Blanchette, Christopher Craver, Kathy W Belk, et al.
Current Medical Research and Opinion|September 7, 2010
Adherence to controller therapy for chronic obstructive pulmonary disease: a reviewMeaghan St Charles, Christopher M Blanchette, Harris Silver, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 12, 2011
Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary diseaseAnand A Dalal, Melissa H Roberts, Hans V Petersen, et al.
Drugs in Context|August 16, 2014
One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USASusan Tsivitse Arthur, Joshua M Noone, Bryce A Van Doren, et al.
Archives of Internal Medicine|January 26, 2005
Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid populationFadia T Shaya, Steven W Blume, Christopher M Blanchette, et al.
Drugs in Context|March 14, 2015
Cachexia & debility diagnoses in hospitalized children and adolescents with complex chronic conditions: evidence from the Kids' Inpatient DatabaseBryce A Van Doren, Debosree Roy, Joshua M Noone, et al.
Advances in Therapy|April 29, 2006
Resource utilization and costs of blood management services associated with knee and hip surgeries in US hospitalsChristopher M Blanchette, Peter Feng Wang, Ashish V Joshi, et al.
Clinicoeconomics and Outcomes Research : CEOR|January 23, 2015
End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseasesSteven M Brunelli, Christopher M Blanchette, Ami J Claxton, et al.
BMC Pulmonary Medicine|November 16, 2024
Higher healthcare cost and utilization before and after diagnosis of AATD in the United StatesChristopher M Blanchette, Sarah Whitmire, Joshua Oh, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 10, 2010
Quarterly assessment of short-acting beta(2)-adrenergic agonist use as a predictor of subsequent health care use for asthmatic patients in the United StatesHarris S Silver, Christopher M Blanchette, Shital Kamble, et al.
Pageof 8